All In Biotech

Drug Trial Radar · NCT00562224

Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients

Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of PCI-24781 Administered Orally in Patients With Advanced Cancer

Last checked: Nov 19, 2026Latest source record: Sep 28, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

36

Planned (sponsor's estimate)

Start

Nov 2007

Primary completion

Jun 2010

Study completion Sep 2010

Sponsor

Lead sponsor
Pharmacyclics LLC.AbbVie (ABBV)
Sponsor type
Industry
First posted
Nov 21, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine the highest dose of study drug that can be taken without causing serious side effects in patients with advanced cancer. The study will look at safety of the study drug and whether the treatment schedule is tolerated by patients.

Conditions

  • Neoplasms by Site
  • Lymphoma, Non-hodgkin
  • Hodgkin Disease
  • Multiple Myeloma
  • Leukemia, Lymphocytic, Chronic

Interventions

  • PCI-24781Drug

    Up to 7 cohorts will receive PCI-24781 orally at doses starting at 30 mg/m2 three times a day approximately 4 hours apart ("TID"), up to 90 mg/m2, administered 5 days/week during the first 21 days of each 28 day cycle until MTD is reached. If a dose limiting toxicity (DLT) occurs, then the next cohort will receive PCI-24781 twice a day approximately 4 hours apart ("BID"). If a DLT occurs on the "BID" schedule, the subsequent cohort will receive PCI-24781 BID for 7 days every other week (2 times in a 28 day cycle). If a DLT occurs on this dosing schedule, then the next cohort will receive PCI-24781 BID for 5 days/week every other week (2 times in a 28 day cycle) until the maximum tolerated dose is reached.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicity assessment at the end of the first 28 day cycle.Time frame: at the end of the first 28 day cycle

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • California Cancer Care

    Greenbrae, California

  • University of Chicago

    Chicago, Illinois

  • Sarah Cannon Research Institue

    Nashville, Tennessee

  • MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.